KYMR (Kymera Therapeutics) Price-to-Tangible-Book : 3.83 (As of Jul. 24, 2025)

Kymera Therapeutics Price-to-Tangible-Book Chart

Kymera Therapeutics Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Price-to-Tangible-Book	Get a 7-Day Free Trial															3.47	2.68	3.43	3.12	2.27

Competitive Comparison of Kymera Therapeutics's Price-to-Tangible-Book

For the Biotechnology subindustry, Kymera Therapeutics's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kymera Therapeutics's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kymera Therapeutics's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Kymera Therapeutics's Price-to-Tangible-Book falls into.

Kymera Therapeutics Price-to-Tangible-Book Calculation

Kymera Therapeutics's price-to-tangible-book ratio for today is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.

Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.

Kymera Therapeutics Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Kymera Therapeutics's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.

Kymera Therapeutics Business Description